Printer Friendly

Impax Laboratories agrees to divest manufacturing facility in Taiwan to Bora Pharmaceuticals.

M2 PHARMA-December 21, 2017-Impax Laboratories agrees to divest manufacturing facility in Taiwan to Bora Pharmaceuticals


United States-based Impax Laboratories has agreed to divest its manufacturing facility in Taiwan (Impax Taiwan) to Taiwan-based Bora Pharmaceuticals, it was reported yesterday.

This sale supports Impax's operational and cost improvement plans to streamline operations and decrease costs.

According to the terms of the agreement, Bora will purchase all of Impax Taiwan's issued share capital and certain loans outstanding between Impax and Impax Taiwan for a total purchase price of USD18.5m. As a result of the sale, Impax expects to record a pre-tax impairment charge of around USD70.0 to USD80.0m in the fourth quarter of 2017. Also, Bora will have the rights to market and sell Impax's branded Parkinson's drug, Rytary (approved as Numient outside the US), in Taiwan. The deal should be finalised in the first quarter of 2018, subject to customary closing conditions.

((Comments on this story may be sent to

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Geographic Code:9TAIW
Date:Dec 21, 2017
Previous Article:Evox Therapeutics signs research collaboration with Boehringer Ingelheim.
Next Article:Wilmington Healthcare names new business development director.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters